Pilz, Jürgen

[["dc.bibliographiccitation.firstpage","42"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ZEITSCHRIFT FUR PSYCHOSOMATISCHE MEDIZIN UND PSYCHOTHERAPIE"],["dc.bibliographiccitation.lastpage","57"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Doering, Stefan"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Adler, L."],["dc.contributor.author","Huether, Gerald"],["dc.date.accessioned","2018-11-07T09:41:12Z"],["dc.date.available","2018-11-07T09:41:12Z"],["dc.date.issued","2001"],["dc.description.abstract","Cortisol is one of the major parameters investigated in psychoneuroendocrinological research, but the methods employed for sample collecting are often unsatisfactory, A suitable method of sample collection should allow for the integrative assessment of long-term changes of the HPA-system, should be non-invasive, and should not exceed the subject's compliance. The assessment of cortisol in night-urine fulfils these demands; although this method has been occasionally employed, it has not yet been described systematically, For the first time a detailed description is given here that allows for a standardized replication. In ten previous studies and three investigations of our own this method has been successfully applied to detect changes in the cortisol excretion of patients with endocrinological and psychiatric disorders as well as in subjects under conditions of psychosocial stress. The determination of cortisol in night-urine represents an ideal method for the assessment of changes in the basal HPA-activity in numerous areas of psychoneuroendocrinological research, e.g. field and screening studies in natural environment, clinical studies in psychiatry and especially follow-up studies in psychotherapy research."],["dc.identifier.isi","000166985000003"],["dc.identifier.pmid","11593453"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33678"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Vandenhoeck & Ruprecht"],["dc.relation.issn","1438-3608"],["dc.title","Cortisol in night-urine: Introduction of a research method in psychoneuroendocrinology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","161"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Neuroscience Letters"],["dc.bibliographiccitation.lastpage","164"],["dc.bibliographiccitation.volume","360"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Guan, Z."],["dc.contributor.author","Pohlmann, K."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.date.accessioned","2018-11-07T10:49:33Z"],["dc.date.available","2018-11-07T10:49:33Z"],["dc.date.issued","2004"],["dc.description.abstract","The pathophysiology of periodic leg movements (PLMs) in sleep remains to be elucidated. Among other hypotheses all alteration of dopaminergic function has been suggested. Nocturnal urinary dopamine and 4-hydroxy-3-methoxyphenylacetic acid excretion in otherwise healthy subjects with PLMs was significantly reduced (P < 0.001 and P < 0.05, respectively) compared to subjects without PLMs. This finding, for the first time, demonstrates a correlate of a functionally relevant hypoactivity of the dopaminergic system in subjects with PLMs. (C) 2004 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.neulet.2004.02.056"],["dc.identifier.isi","000221141400013"],["dc.identifier.pmid","15082158"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48459"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ireland Ltd"],["dc.relation.issn","0304-3940"],["dc.title","Nocturnal urinary dopamine excretion is reduced in otherwise healthy subjects with periodic leg movements in sleep"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Meier, A."],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Kornhuber, Johannes"],["dc.contributor.author","Bleich, Stefan"],["dc.date.accessioned","2018-11-07T10:56:34Z"],["dc.date.available","2018-11-07T10:56:34Z"],["dc.date.issued","2005"],["dc.format.extent","252"],["dc.identifier.isi","000232591900119"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50044"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","24th Symposium of the Arbeitsgemeinschaft-fur-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","239"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neural Transmission"],["dc.bibliographiccitation.lastpage","254"],["dc.bibliographiccitation.volume","113"],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Meier, A."],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Kornhuber, Johannes"],["dc.contributor.author","Bleich, Stefan"],["dc.date.accessioned","2018-11-07T10:23:16Z"],["dc.date.available","2018-11-07T10:23:16Z"],["dc.date.issued","2006"],["dc.description.abstract","Assessment of reactive oxygen species (ROS) is highly important in neurodegenerative disorders and neuroleptic treatment. However, conflicting results have been reported, which may arise from methodological difficulties. Obstructive sleep apnea (OSA) syndrome with episodic hypoxia-reoxygenation is proposed as a human model for the investigation of ROS measurements. Despite a broad analytical approach comprising lipid peroxidation and amino acid oxidation products, oxidative DNA damage, and activity of the antioxidant defense, only plasma malondialdehyde (MDA) and urinary o,o'-dityrosine seemed to be appropriate, robust biomarkers of oxidative stress, which are also simple enough for routine clinical use. MDA concentrations correlated with a duration of nocturnal desaturation below 85% (r = 0.77, p < 0.0005), and o,o'-dityrosine levels decreased after therapy (p < 0.05) as a function of baseline concentrations (r = -0.61, p < 0.05). Gender effects in ROS generation also have to be considered. At present, we recommend the application of several oxidative stress measurements at different time points, preferably involving plasma MDA and urinary o,o'-dityrosine."],["dc.identifier.doi","10.1007/s00702-005-0316-2"],["dc.identifier.isi","000234752500013"],["dc.identifier.pmid","15959848"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42424"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0300-9564"],["dc.title","Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2095"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","The Journal of Infectious Diseases"],["dc.bibliographiccitation.lastpage","2098"],["dc.bibliographiccitation.volume","181"],["dc.contributor.author","Bottcher, T."],["dc.contributor.author","Gerber, Joachim"],["dc.contributor.author","Wellmer, A."],["dc.contributor.author","Smirnov, A. V."],["dc.contributor.author","Fakhrjanali, F."],["dc.contributor.author","Mix, E."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Zettl, Uwe K."],["dc.contributor.author","Nau, R."],["dc.date.accessioned","2018-11-07T10:48:14Z"],["dc.date.available","2018-11-07T10:48:14Z"],["dc.date.issued","2000"],["dc.description.abstract","Bacterial compounds induce the production of reactive oxygen species (ROS) in meningitis. Rifampin releases smaller quantities of proinflammatory compounds from Streptococcus pneumoniae than do beta-lactam antibiotics. Therefore, rabbits infected intracisternally with S. pneumoniae were treated intravenously either with rifampin 5 mg/kg/h or ceftriaxone 10 mg/kg/h (n = 9 each). Before initiation of antibiotic treatment, a strong positive correlation between ROS production of cerebrospinal fluid (CSF) phagocyte populations and bacterial CSF titers was observed (granulocytes: r(s) = .90, P < .0001; monocytes: r(s) = .81, P < .0001). CSF leukocytes from rifampin-treated rabbits produced less ROS (monocytes at 2 h after initiation of treatment: P = .045; at 5 h: P = .014; granulocytes at 5 h: P = .036) than did leukocytes from animals receiving ceftriaxone. The CSF malondialdehyde concentrations and the density of apoptotic neurons in the dentate gyrus were lower in rifampin- than in ceftriaxone-treated animals (P = .002 and .005). The use of rifampin to reduce the release of ROS and to decrease secondary brain injury appears promising."],["dc.identifier.doi","10.1086/315518"],["dc.identifier.isi","000087923900038"],["dc.identifier.pmid","10837202"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48141"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Univ Chicago Press"],["dc.relation.issn","0022-1899"],["dc.title","Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","332"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Acta Neurologica Scandinavica"],["dc.bibliographiccitation.lastpage","334"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Bleich, S."],["dc.contributor.author","Kropp, S."],["dc.contributor.author","Degner, D."],["dc.contributor.author","Zerr, I."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Gleiter, C. H."],["dc.contributor.author","Otto, M."],["dc.contributor.author","Rüther, E."],["dc.contributor.author","Kretzschmar, H. A."],["dc.contributor.author","Wiltfang, J."],["dc.contributor.author","Kornhuber, J."],["dc.contributor.author","Poser, S."],["dc.date.accessioned","2017-09-07T11:44:36Z"],["dc.date.available","2017-09-07T11:44:36Z"],["dc.date.issued","2000"],["dc.description.abstract","Objectives– Substantial evidence supports the hypothesis that oxygen free radicals are involved in various neurodegenerative disorders. To assess the presence of oxidative stress in Creutzfeldt–Jakob disease (CJD) we examined the concentrations of malondialdehyde (MDA) as an established marker of lipid peroxidation. Material and methods– MDA was quantified by high performance liquid chromatography (HPLC) in cerebrospinal fluid (CSF; n=12) and in serum (n=11) samples of CJD patients and healthy controls (n=15). Results– Mean values in healthy controls: 2.56 nmol/ml±0.46 (CSF) and 1.94 nmol/ml±0.67 (serum); mean values in CJD patients: 2.64 nmol/ml±0.67 (CSF) and 1.68 nmol/ml±0.79 (serum). No significant (P>0.05) difference between CJD patients and controls was observed. Conclusions– The results indicated that the CSF and serum of CJD patients showed no higher endogenous levels of MDA as compared to normal healthy controls. These findings provide no evidence for an additional role of oxidative stress in the pathogenetic mechanism underlying CJD neurodegeneration."],["dc.identifier.doi","10.1034/j.1600-0404.2000.9s290a.x"],["dc.identifier.gro","3151697"],["dc.identifier.pmid","10987323"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8516"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.relation.issn","0001-6314"],["dc.title","Creutzfeldt-Jakob disease and oxidative stress"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","231"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","ACTA PHYSIOLOGICA SCANDINAVICA"],["dc.bibliographiccitation.lastpage","235"],["dc.bibliographiccitation.volume","174"],["dc.contributor.author","Freudenthaler, S. M."],["dc.contributor.author","Schreeb, K. H."],["dc.contributor.author","Wiese, A."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Gleiter, Christoph H."],["dc.date.accessioned","2018-11-07T10:31:12Z"],["dc.date.available","2018-11-07T10:31:12Z"],["dc.date.issued","2002"],["dc.description.abstract","The present study was carried out to evaluate a model of a hypoxic stimulus of erythropoietin (EPO) production in humans and to investigate the role of free oxygen radicals in human EPO production. The study was conducted as an open, randomized, parallel, placebo-controlled trial. Thirty-six healthy male volunteers received a hypoxic treatment (13% O-2) with a respiration mask for 6 h. During the period of hypoxia, the volunteers received as a short-term treatment either 1200 mg thioctic acid, or N-acetylcysteine 600 mg or placebo (0.9% sodium chloride). The EPO concentration in plasma increased up to 290% of the baseline level in all three groups. No statistically significant differences of AUC(EPO(0-48 h)) could be demonstrated between the groups. The malondialdehyde (MDA) concentration in plasma increased significantly (P<0.001) 2 h after termination of hypoxia (mean 129.8&PLUSMN;6.8% of the baseline) in all three groups. Conclusions: Taken together, our in-vivo results do not support a gross modulatory effect of a short-term treatment with radical scavenging agents on EPO-production during or after hypoxia in humans, as derived from the detected changes of MDA-concentrations in peripheral plasma."],["dc.identifier.doi","10.1046/j.1365-201x.2002.00946.x"],["dc.identifier.isi","000174423200004"],["dc.identifier.pmid","11906322"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44052"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Ltd"],["dc.relation.issn","0001-6772"],["dc.title","Influence of controlled hypoxia and radical scavenging agents on erythropoietin and malondialdehyde concentrations in humans"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Nolte, Wilhelm"],["dc.contributor.author","von Heppe, J."],["dc.contributor.author","Bahn, Erik"],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Hajak, G."],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Ramadori, G."],["dc.contributor.editor","Hüther, Gerald"],["dc.contributor.editor","Kochen, Walter"],["dc.contributor.editor","Simat, Thomas J."],["dc.contributor.editor","Steinhart, Hans"],["dc.date.accessioned","2017-09-07T11:44:27Z"],["dc.date.available","2017-09-07T11:44:27Z"],["dc.date.issued","2011"],["dc.description.abstract","Neuropsychiatric symptoms due to any type of dysfunction and/or portal-systemic shunting are summarized as hepatic encephalopathy (HE). HE in the presence of liver cirrhosis and/or portal-systemic shunting has been termed portal-systemic encephalopathy (PSE). PSE is most frequent among the HE syndromes and is almost exclusively seen in patients with advanced cirrhosis and portal hypertension. Portal-systemic shunting either spontaneous due to portal hypertension, following surgical portocaval anastomosis, or subsequent to transjugular intrahepatic portosystemic stent-shunt (TIPSS) is regarded as the primary causative condition for PSE, not hepatic dysfunction per se. PSE may be considered as a disorder of multiple neurotransmitter systems among which derangements of the seroton-ergic system have been documented most consistently. Incipient PSE is frequently paralleled by the occurence of sleep disorders, however, their relation to PSE remains unclear. We observed a transient increase of sleep disorders post-TIPSS, which were only in part correlated to other symptoms of PSE. Among the biochemical parameters studied only an association between arterial ammonia levels and sleep disorders became apparent, whereas no significat relation was observed for peripheral tryptophan."],["dc.identifier.doi","10.1007/978-1-4615-4709-9_22"],["dc.identifier.gro","3151664"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8481"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","chake"],["dc.publisher","Springer"],["dc.publisher.place","Boston, MA"],["dc.relation.crisseries","Advances in Experimental Medicine and Biology"],["dc.relation.isbn","978-1-4613-7133-5"],["dc.relation.ispartof","Advances in Experimental Medicine and Biology"],["dc.relation.ispartofseries","Advances in Experimental Medicine and Biology"],["dc.relation.issn","0065-2598"],["dc.title","Sleep Disorders and Portal-Systemic Encephalopathy Following Transjugular Intrahepatic Portosystemic Stent Shunt in Patients with Liver Cirrhosis"],["dc.type","book_chapter"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","315"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"],["dc.bibliographiccitation.lastpage","325"],["dc.bibliographiccitation.volume","742"],["dc.contributor.author","Pilz, Jürgen"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Gleiter, Christoph H."],["dc.date.accessioned","2021-06-01T10:50:16Z"],["dc.date.available","2021-06-01T10:50:16Z"],["dc.date.issued","2000"],["dc.description.abstract","We established a method for the detection of free and total (free and bound) malondialdehyde (MDA) in human plasma samples after derivatisation with 2,4-dinitrophenylhydrazine (DNPH). Free MDA was prepared by perchloric acid deproteinisation whereas an alkaline hydrolysation step for 30 min at 60 degrees C was introduced prior to protein precipitation for the determination of total MDA. Derivatisation was accomplished in 10 min at room temperature subsequently chromatographed by HPLC on a reversed-phase 3 mu m C-18 column with UV detection (310 nm). The detection limit was 25 pmol/ml for free and 0.3 nmol/ml for total MDA. The recovery of MDA added to different human plasma samples was 93.6% (n=11; RSD 7.1%) for the hydrolysation procedure. In samples from 12 healthy volunteers who underwent a hypoxic treatment (13% O-2 for 6 h) we estimated a baseline value of total MDA of 2.16 nmol/ml (SD 0.29) (ambient air) with a significant increase to 2.92 (nmol/ml, SD 0.57; P=0.01) after the end of this physiological oxidative stress challenge. Plasma values of free MDA in these samples were close to our detection limit. The presented technique can easily performed with an isocratic HPLC apparatus and provides highly specific results for MDA as do sophisticated GC-MS methods. (C) 2000 Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0378-4347(00)00174-2"],["dc.identifier.isi","000087713300011"],["dc.identifier.pmid","10901136"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86593"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0378-4347"],["dc.title","Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Sleep Research"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Schabus, M."],["dc.contributor.author","Hasselhorn, Marcus"],["dc.contributor.author","Huether, Gerald"],["dc.contributor.author","Mavridou, K."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Schneider, B."],["dc.contributor.author","Wiater, A."],["dc.date.accessioned","2018-11-07T11:08:43Z"],["dc.date.available","2018-11-07T11:08:43Z"],["dc.date.issued","2008"],["dc.format.extent","48"],["dc.identifier.isi","000262850300118"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52851"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell Publishing, Inc"],["dc.publisher.place","Malden"],["dc.relation.conference","19th Congress of the European-Sleep-Research-Society"],["dc.relation.eventlocation","Glasgow, SCOTLAND"],["dc.relation.issn","0962-1105"],["dc.title","Effects of parental evening interventions on stress, sleep, and school performance"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]